|
|
|
|
Am J Emerg Med 2009,May,01;27(4):509-10; author reply 510; (PMID: 19555629)
|
|
|
Curr Med Res Opin 2009,May,01;25(5):1179-96; (PMID: 19323613)
OBJECTIVE: To evaluate efficacy and tolerability of once-daily cyclobenzaprine extended release (CER) 15- and 30-mg capsules in patients with muscle spasm associated with acute, [...]
|
|
|
Gen Hosp Psychiatry 2009,May,01;31(3):206-19; (PMID: 19410099)
[...]) or tramadol; (3) gabapentin, duloxetine or pregabalin if neuropathic pain; (4) cyclobenzaprine, pregabalin, duloxetine, or milnacipran for fibromyalgia; (5) topical analgesics (capsaicin, [...]
|
|
|
Int J Clin Pharmacol Ther 2009,Apr,01;47(4):269-74; (PMID: 19356393)
OBJECTIVE: To evaluate the systemic bioavailability of a new controlled release cyclobenzaprine tablet, and the influence of a high fat meal on its bioavailability. SUBJECTS, MATERIALS AND METHODS: 24 and 12 healthy male subjects were recruited for the bioavailability and influence of diet studies, respectively.[...]
|
|
|
Am J Health Syst Pharm 2009,Jan,15;66(2):142-8; (PMID: 19139478)
[...]) 15 mg by mouth once five days prior for a school examination, and hydrocodone-acetaminophen and cyclobenzaprine for pain. His social history revealed a recent increase in his exercise regimen, and his last alcoholic beverage was consumed five days prior.[...]
|
|
|
Clin Ther 2009,Jan,01;31(1):108-14; (PMID: 19243711)
[...]OBJECTIVE: The purpose of this study was to compare the pharmacokinetics and tolerability of single oral doses of cyclobenzaprine extended-release (CER) 15- and 30-mg capsules. METHODS: This was a randomized, double-blind, 2-period crossover study in healthy adults aged 18 to 40 years.[...]
|
|
|
Drugs Aging 2009,Jan,01;26(2):95-101; (PMID: 19220066)
BACKGROUND AND OBJECTIVE: The clinical utility of cyclobenzaprine for the treatment of muscle spasm associated with acute, painful musculoskeletal conditions is limited by cholinergic adverse effects associated with its use.[...]
|
|
|
Clin Drug Investig 2009,Jan,01;29(3):145-52; (PMID: 19243207)
[...]BACKGROUND AND OBJECTIVE: Food can alter the bioavailability of the controlled-release formulations of many different drugs. This study assessed the effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release (CER) in healthy adult subjects. METHODS: Healthy adult volunteers were randomized in an open-label, two-period crossover design to receive a single dose of CER 30 mg on days 1 and 15 (separated by a 14-day drug washout) in either the fed or the fasted state.[...]
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(3):CD006830; (PMID: 19588406)
[...]TPs can produce a characteristic pattern of irradiated pain or autonomic symptoms when stimulated. Cyclobenzaprine, a muscle relaxant that suppresses muscle spasm without interfering with muscle function, is used in clinical management of [...]
|
|
|
Pharmacology 2009,Jan,01;84(2):91-2; (PMID: 19590258)
The muscle-relaxing 5-HT(2) receptor antagonist cyclobenzaprine is structurally closely related to amitriptyline. It is widely used to treat patients presenting with [...]
|
 1 2 3 4 5 6 7 8 
|
|
